Literature DB >> 21270815

L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.

Hiroe Toba1, Mamiko Yoshida, Chisato Tojo, Arisa Nakano, Yuko Oshima, Yushi Kojima, Kazuki Noda, Jiahong Wang, Miyuki Kobara, Tetsuo Nakata.   

Abstract

Cilnidipine, an N/L-type calcium channel blocker, has been reported to inhibit sympathetic nerve activity and has a greater renoprotective effect than L-type calcium channel blockers. To investigate the hypothesis that cilnidipine might ameliorate advanced hypertensive nephropathy and inhibit the renal renin-angiotensin-aldosterone system, cilnidipine (1 mg per kg per day) or amlodipine (1 mg per kg per day) was administered to uninephrectomized deoxycorticosterone (DOCA)-salt hypertensive rats (DOCA-salt) for 4 weeks by gavage. Although the blood pressure in the DOCA-salt group was higher than that of control, neither cilnidipine nor amlodipine had any effect on the increase in blood pressure in the DOCA-salt group. The DOCA (40 mg per kg per week, subcutaneously (s.c.)) and salt (1% NaCl in drinking water) treatment significantly aggravated the levels of urinary protein excretion and creatinine clearance and increased glomerulosclerosis and collagen deposition in the tubulointerstitial area of the kidney. These effects were attenuated by cilnidipine treatment. Reverse transcription-polymerase chain reaction analysis revealed that the renal expression of mRNA for collagen I/IV and transforming growth factor-β was enhanced in the DOCA-salt group and that the overexpression of these molecules was suppressed by cilnidipine. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived superoxide production in the kidney and urinary norepinephrine excretion, which were enhanced in the DOCA-salt group, were suppressed by cilnidipine. Cilnidipine also decreased the activity and expression of angiotensin-converting enzyme (ACE) and the aldosterone concentration in the renal homogenate. Although neither cilnidipine nor amlodipine had any effect on the increased blood pressure in the DOCA-salt group, these renal changes were not induced by treatment with amlodipine. In conclusion, cilnidipine inhibited renal dysfunction, sympathetic nerve activity and renal renin-angiotensin-aldosterone system in the DOCA-salt group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270815     DOI: 10.1038/hr.2010.279

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  12 in total

1.  L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

Authors:  Shizuka Aritomi; Tomoyuki Konda; Michihiro Yoshimura
Journal:  Heart Vessels       Date:  2011-10-12       Impact factor: 2.037

2.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

Review 3.  Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies.

Authors:  Mayakalyani Srivathsan; Vikram Vardhan; Azra Naseem; Sayali Patil; Vivek Rai; Deepakkumar G Langade
Journal:  Cureus       Date:  2022-08-10

4.  L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Authors:  Masanori Abe; Noriaki Maruyama; Hiroko Suzuki; Atsushi Inoshita; Yoshinori Yoshida; Kazuyoshi Okada; Masayoshi Soma
Journal:  Heart Vessels       Date:  2012-08-23       Impact factor: 2.037

5.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

6.  How full is our antihypertensives pipeline?

Authors:  Dilip Gude
Journal:  J Pharmacol Pharmacother       Date:  2012-01

7.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11

8.  Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel.

Authors:  Keiichiro Mishima; Masao Nakasatomi; Shunsuke Takahashi; Hidekazu Ikeuchi; Toru Sakairi; Yoriaki Kaneko; Keiju Hiromura; Yoshihisa Nojima; Akito Maeshima
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

9.  Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients.

Authors:  Yutaka Kawabata; Takeshi Soeki; Hiroyuki Ito; Tomomi Matsuura; Kenya Kusunose; Takayuki Ise; Koji Yamaguchi; Takeshi Tobiume; Shusuke Yagi; Daiju Fukuda; Hirotsugu Yamada; Tetsuzo Wakatsuki; Mitsuhiro Kitani; Kazuhiro Kawano; Yoshio Taketani; Masataka Sata
Journal:  Int J Hypertens       Date:  2020-12-22       Impact factor: 2.420

10.  Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.

Authors:  Shinji Takai; Denan Jin; Shizuka Aritomi; Kazumi Niinuma; Mizuo Miyazaki
Journal:  Hypertens Res       Date:  2012-11-29       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.